Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Neoplasms | 3 | 2019 | 189 | 1.050 |
Why?
|
| Diagnostic Imaging | 4 | 2019 | 1162 | 0.940 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2019 | 7551 | 0.830 |
Why?
|
| Pelvis | 3 | 2014 | 362 | 0.800 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 255 | 0.790 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2020 | 7702 | 0.690 |
Why?
|
| Adrenal Cortex | 1 | 2018 | 35 | 0.670 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 146 | 0.610 |
Why?
|
| Appendiceal Neoplasms | 2 | 2017 | 234 | 0.610 |
Why?
|
| Leiomyoma | 1 | 2018 | 145 | 0.580 |
Why?
|
| Stomach Neoplasms | 9 | 2021 | 2278 | 0.550 |
Why?
|
| Surgical Flaps | 2 | 2014 | 927 | 0.550 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2018 | 223 | 0.550 |
Why?
|
| Endometrial Neoplasms | 3 | 2020 | 1341 | 0.530 |
Why?
|
| Pelvic Exenteration | 1 | 2015 | 108 | 0.500 |
Why?
|
| Calcinosis | 1 | 2017 | 423 | 0.470 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2019 | 1833 | 0.450 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 519 | 0.440 |
Why?
|
| Thigh | 1 | 2014 | 172 | 0.440 |
Why?
|
| Esophageal Neoplasms | 7 | 2021 | 3168 | 0.430 |
Why?
|
| Esophagogastric Junction | 4 | 2021 | 543 | 0.410 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2021 | 833 | 0.390 |
Why?
|
| Uterine Neoplasms | 3 | 2020 | 545 | 0.350 |
Why?
|
| Abdominal Neoplasms | 2 | 2019 | 231 | 0.270 |
Why?
|
| Adenocarcinoma | 6 | 2022 | 7789 | 0.260 |
Why?
|
| Multimodal Imaging | 3 | 2019 | 550 | 0.250 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 669 | 0.250 |
Why?
|
| Chemoradiotherapy | 3 | 2019 | 1946 | 0.240 |
Why?
|
| Peritoneal Neoplasms | 3 | 2015 | 821 | 0.240 |
Why?
|
| Positron-Emission Tomography | 3 | 2019 | 2173 | 0.230 |
Why?
|
| Neoplasm Staging | 11 | 2020 | 13658 | 0.230 |
Why?
|
| Patient Positioning | 2 | 2015 | 195 | 0.230 |
Why?
|
| Image Enhancement | 3 | 2015 | 561 | 0.220 |
Why?
|
| Middle Aged | 22 | 2021 | 86204 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2018 | 1226 | 0.190 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 5767 | 0.190 |
Why?
|
| Female | 26 | 2021 | 141928 | 0.190 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2020 | 37 | 0.180 |
Why?
|
| Ischium | 1 | 2019 | 10 | 0.180 |
Why?
|
| Humans | 35 | 2022 | 261506 | 0.170 |
Why?
|
| Endometrium | 2 | 2019 | 470 | 0.160 |
Why?
|
| Patient Selection | 2 | 2017 | 2055 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2018 | 58 | 0.150 |
Why?
|
| Adrenalectomy | 1 | 2018 | 188 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2019 | 222 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2022 | 29902 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 2019 | 253 | 0.150 |
Why?
|
| Tumor Burden | 3 | 2020 | 1987 | 0.140 |
Why?
|
| Hypercalcemia | 1 | 2017 | 137 | 0.140 |
Why?
|
| Aged | 17 | 2022 | 70117 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 15862 | 0.140 |
Why?
|
| Ablation Techniques | 1 | 2018 | 148 | 0.140 |
Why?
|
| Adult | 17 | 2021 | 77950 | 0.140 |
Why?
|
| Radiography, Abdominal | 1 | 2016 | 120 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2019 | 1863 | 0.130 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 402 | 0.130 |
Why?
|
| Preoperative Care | 3 | 2016 | 1529 | 0.130 |
Why?
|
| Peritoneal Diseases | 1 | 2015 | 29 | 0.130 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2015 | 38 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 408 | 0.130 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2016 | 170 | 0.130 |
Why?
|
| Liposarcoma | 1 | 2016 | 214 | 0.120 |
Why?
|
| Digestive System Diseases | 1 | 2014 | 35 | 0.120 |
Why?
|
| Prognosis | 8 | 2022 | 21713 | 0.120 |
Why?
|
| Urologic Diseases | 1 | 2014 | 78 | 0.120 |
Why?
|
| Vaginal Neoplasms | 1 | 2015 | 152 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 4892 | 0.120 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 5112 | 0.110 |
Why?
|
| Prostatectomy | 1 | 2018 | 962 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2015 | 289 | 0.110 |
Why?
|
| Male | 15 | 2021 | 123000 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2019 | 32848 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 436 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 1202 | 0.100 |
Why?
|
| Young Adult | 3 | 2018 | 21445 | 0.090 |
Why?
|
| Cancer Survivors | 1 | 2017 | 650 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2015 | 510 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2014 | 739 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 14889 | 0.090 |
Why?
|
| Survival Rate | 6 | 2021 | 12221 | 0.090 |
Why?
|
| Pregnancy | 2 | 2019 | 7573 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 3 | 2017 | 4975 | 0.090 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 14289 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2018 | 12873 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 4744 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2017 | 6100 | 0.080 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 1742 | 0.080 |
Why?
|
| Retrospective Studies | 9 | 2022 | 37905 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 4988 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4078 | 0.070 |
Why?
|
| Organoplatinum Compounds | 2 | 2019 | 702 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4654 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2016 | 344 | 0.060 |
Why?
|
| Melanoma | 1 | 2021 | 5317 | 0.060 |
Why?
|
| Fluorouracil | 2 | 2019 | 1944 | 0.060 |
Why?
|
| Esophagectomy | 2 | 2019 | 911 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10331 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4638 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5542 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2021 | 271 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 8865 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 4971 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 50 | 0.040 |
Why?
|
| Leucovorin | 1 | 2019 | 332 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 202 | 0.040 |
Why?
|
| Adolescent | 1 | 2017 | 31252 | 0.040 |
Why?
|
| Endosonography | 1 | 2019 | 536 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6207 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 671 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 565 | 0.030 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 411 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 1283 | 0.030 |
Why?
|
| Peritoneum | 1 | 2015 | 150 | 0.030 |
Why?
|
| Splenic Diseases | 1 | 2014 | 56 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 875 | 0.030 |
Why?
|
| Nomograms | 1 | 2016 | 313 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 183 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 121 | 0.030 |
Why?
|
| Taxoids | 1 | 2016 | 967 | 0.030 |
Why?
|
| Abdomen | 1 | 2014 | 332 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2014 | 246 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 3443 | 0.030 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2015 | 475 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 1031 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1301 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3890 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5673 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1656 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2014 | 574 | 0.020 |
Why?
|
| Contrast Media | 1 | 2015 | 1472 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 15193 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.020 |
Why?
|
| Proton Therapy | 1 | 2017 | 1577 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3981 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 5377 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2014 | 1824 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1411 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6009 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2016 | 3518 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 10001 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17523 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16273 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 10035 | 0.010 |
Why?
|